ICICI Bank Limited, together with its subsidiaries, engages in the provision of various banking and financial services to retail and corporate customers in India and internationally. The company operates through Retail Banking, Wholesale Banking, Treasury, Other Banking, Life Insurance, and Others segments. It accepts savings, salary, pension, current, trade, escrow, foreign currency, and vostro accounts, as well as time, fixed, recurring, and security deposits services. The company also provides home, car, two-wheeler, personal, gold, and commercial business loans, as well as loans against securities and other loans; business loans, including working capital finance, term loans, collateral free loans, loans without financials, finance for importers and exporters, and overdraft facilities, as well as loans for new entities and card swipes; and credit, debit, prepaid, travel, forex, and corporate cards. In addition, it offers pockets wallet; fixed income products; investment products, such as mutual funds, gold monetization schemes, initial public offerings, and other online investment services; and agri and rural business, farmer finance, tractor loans, and micro banking services. Further, the company provides portfolio management, trade, foreign exchange, locker, private and NRI banking, and cash management services; family wealth and demat accounts; commercial and investment banking, capital market, custodial, and institutional banking services; health, personal accident, fire, and motor insurance, as well as distributes general and life insurance products; and Internet, mobile, and phone banking services. Additionally, it offers securities investment, broking, trading, and underwriting services; and merchant banking, trusteeship, housing finance, pension fund management, asset management, investment advisory, points of presence, and private equity/venture capital fund management services. The company was founded in 1955 and is headquartered in Mumbai, India.

ICICI Bank Limited

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Molecular Partners (MOLN – Research Report) and SI-B...

Analysts Offer Insights on Healthcare Companies: Molecular Partners (MOLN) and SI-Bone (SIBN)

Vela Technologies ( ($GB:CHP) ) has shared an announcement. Caledonian Holdings has committed a further £750,000 in short-term funding to its inves...

Caledonian Holdings Injects Further £750,000 into SME-Focused Bank AlbaCo

In a report released yesterday, from IDBI Capital maintained a Buy rating on ICICI Bank Limited, with a price target of INR1,640.00. The company’s ...

ICICI Bank Limited (ICICIBANK) Receives a Buy from IDBI Capital

In a report released today, Lim Rui Wen from DBS maintained a Buy rating on Icici Bank, with a price target of $37.50. Rui Wen covers the Financial...

Icici Bank (IBN) Gets a Buy from DBS

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Belite Bio, Inc. ADR (BLTE – Research Report), Sig...

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Sight Sciences (SGHT) and SI-Bone (SIBN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report), SI-Bone (SIBN – R...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH)

U.S. stocks ended the week higher as investors balanced softer hiring data with new government support for housing and stronger momentum in energy ...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 11

Jefferies analyst Rong Li maintained a Buy rating on SI-Bone today and set a price target of $28.00. Currently, the analyst consensus on SI-Bone is...

Jefferies Remains a Buy on SI-Bone (SIBN)

Icici Bank ( ($IBN) ) has issued an update. On January 6, 2026, ICICI Bank disclosed that India’s Pension Fund Regulatory and Development Authority...

Current Quarter	$0.41	Next Quarter	$0.43
Current Year	$1.56	Next Year	$1.79
QoQ Growth	+4.9%	YoY Growth	+14.7%
3Y EPS CAGR	N/A	Target Price	$39.63
Consensus	Buy	Upside	+29.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IBN	$30.57	-0.59%	5.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IBN	$30.57	-0.6%	5.23M
3
4
5
6

IBN

IBN

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get ICICI Bank Limited Data in Excel

Get ICICI Bank Limited Data in Excel